Phase 1/2 trial of intradermal GLS-5300

Trial Profile

Phase 1/2 trial of intradermal GLS-5300

Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs GLS 5300 (Primary)
  • Indications Middle East respiratory syndrome coronavirus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GeneOne Life Science
  • Most Recent Events

    • 20 Sep 2017 New trial record
    • 18 Sep 2017 According to an Inovio Pharmaceuticals media release, The International Vaccine Institute (IVI) is fully funding this trial utilizing a $34 million grant Samsung Foundation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top